Takeda Won’t Face Norwich Copies of Vyvanse ADHD Drug—This Year

Norwich Pharmaceuticals Inc.’s proposed copy of Takeda Pharmaceutical Co.’s Vyvanse can’t gain regulatory approval until at least Jan. 30, a New Jersey federal judge said.

Judge Stanley R. Chesler approved their pact so he has more time to rule on whether nine patents for the ADHD drug are infringed or invalid.

He gave Norwich, a unit of Alvogen Group Inc., one business day to tell the US Food and Drug Administration about the order and to provide a copy, according to an order issued Thursday in the US District Court for the District of New Jersey.

Before Aug. ...